Expression profile of receptor activator of nuclear-κb (rank), rank ligand (rankl) and osteoprotegerin (OPG) in breast cancer

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 199-206

  Owen, Sioned ^a   Ye, Lin ^a   Sanders, Andrew J ^a   Mason, Malcolm D ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Bone metastasis; Breast cancer; MCF 7; MDA MB 231; Oestrogen; OPG; Osteoprotegerin; RANK; RANKL

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTICLE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE NEOPLASMS; BREAST NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPROTEGERIN; PROGNOSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 84873039798     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S and Wang CY: NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13: 62-69, 2007.
2. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
3. Yin JJ, Pollock CB and Kelly K: Mechanisms of cancer metastasis to the bone. Cell Res 15(1): 57-62, 2005.
4. Khosla S: Minireview: The OPG/RANKL/RANK system: Endocrinology 142(12): 5050-5055, 2001.
5. Cecchini MG, Wetterwald A, van der Pluijm G and Thalmann GN: Molecular and biological mechanisms of bone metastasis: EAU Update Series 3: 214-226, 2005.
6. Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y and Amadori D: Role of RANK, RANKL, OPG and CXCR 11(6): 369-375, 2011.
7. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R and Penninger JM: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50, 2000.
8. Liu C, Walter TS, Huang P, Zhang S, Zhu X, Wu Y, Wedderburn LR, Tang P, Owens RJ, Stuart DI, Ren J and Gao B: Structural and functional insights of RANKL-RANK interaction and signalling. J Immunol 184: 6910-6919, 2010.
9. Reid P and Holen I: Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol pp. 1-17, 2009.
10. Hanada R, Hanada T and Penninger JM: Physiology and pathophysiology of the RANKL/RANK system: Biol Chem 391: 1365-1370, 2010.
11. Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKLRANK signalling in osteoclastogenesis and bone disease: Trends Mol Medi 12: 17-25, 2006.
12. Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis: Clin Exp Metastasis 25: 119-129, 2008.
13. Jones HD, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha, Wada T and Penninger JM: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696, 2006.
14. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Tarpley G van, Derby P, Lee R and Boyle WJ: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
15. Kostenuik PJ: Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength: Curr Opin Pharmacol 5: 618-625, 2005.
16. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC and Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL: J Biol Chem 273: 14363-14367, 1998.
17. Poznak CV, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE and Holen I: Expression of osteoprotegerin (OPG), TNF-related apoptosis-inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in breast tumours: J Clin Pathol 59: 56-63, 2006.
18. Lam J, Nelson CA, Ross FP, Teitelbaum SL and Fremont DH: Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity: Journal of Clin Invest 108: 971-979, 2001.
19. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71, 2008.
20. Reinholz MM, Iturria SJ and Roche PC: Differential gene expression of TGF-β family members and osteopontin in breast tumour tissue: Analysis by real-time quantitative PCR. Breast Cancer Res Treat 74: 255-69, 2002.
21. Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin JT and Gillespie MT: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458, 1999.
22. Kitazawa S and Kitazawa R: RANK ligand is a prerequisite for cancer associated osteolytic lesions. J Pathol 198: 228-236, 2002.
23. Zhang L, Teng, Y, Zhang Y, Liu J, Qu J, Hou K, Yang X, Liu Y and Qu X: Receptor activator for nuclear factor κB expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 65: 36-40, 2012.
24. Rachner TD, Schoppet M, Niebergall U and Hofbauer LC: 17β-Estradiol inhibits osteoprotegerin production by the estrogen receptor-α-positive human breast cancer cell line MCF-7. Biochem Biophys Res Commun 368: 736-741, 2008.
25. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS and Gerstenfeld LC: Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated with osteolytic disease: Cancer Res 64: 4506-4513, 2004.
26. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB and Stein GS: Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo: Proc Natl Acad Sci USA 102: 1454-1459, 2005.
27. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY et al: The bone specific expression of RUNX2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts: J Biol Chem 280: 20274-20285, 2005.
28. Inman CK and Shore P: The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278: 48684-48689, 2003.
29. Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K and Komori T: Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in RUNX2 -/- mice by RANKL transgene: J Biol Chem 278: 23971-23977, 2003.